Sy­neos up for sale — re­port; Takeda's Nin­laro fails PhI­II in mul­ti­ple myelo­ma; EMA braces for drug short­age

→ Amid in­dus­try-wide con­sol­i­da­tion, the CRO Sy­neos is con­sid­er­ing putting it­self up for sale, Reuters re­ports, and has hired Cen­ter­view Part­ners to so­lic­it of­fers. The com­pa­ny was it­self formed by a merg­er be­tween INC Re­search and in­Ven­tiv Health. It fo­cus­es on help­ing biotechs and phar­ma­ceu­ti­cal com­pa­nies com­plete late-stage tri­als.

→ Just a day af­ter Bris­tol My­ers Squibb con­ced­ed fail­ure in a tri­al com­bin­ing its Em­plic­i­ti with Cel­gene’s long-run­ning block­buster Revlim­id and a steroid for front­line mul­ti­ple myelo­ma, Take­da said it didn’t have any luck with Nin­laro, ei­ther. Fo­cus­ing on trans­plant in­el­i­gi­ble pa­tients, in­ves­ti­ga­tors found that adding Nin­laro to Revlim­id and dex­am­etha­sone im­proved pro­gres­sion-free sur­vival by around 13.5 months but the re­sult was not sta­tis­ti­cal­ly sig­nif­i­cant.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER